Market Place
Sourcing Support
Gossamer Announces Early Results of Convertible Notes Exchange
03 Jun 2026 //
FIRSTWORD PHARMA
Gossamer Extends Tender Date for Convertible Notes Exchange Offer
02 Jun 2026 //
BUSINESSWIRE
Gossamer Bio Launches Exchange Offer to Eliminate $120M+ in Debt
18 May 2026 //
PHARMIWEB
Gossamer Bio Reports Q1 2026 Financial Results and Update
18 May 2026 //
PHARMIWEB
Gossamer Bio to Report Q1 2026 Results and Host Webcast on May 18
15 May 2026 //
BUSINESSWIRE
Gossamer, Biomx Reveal Hefty Staff Cuts
21 Mar 2026 //
BIOSPACE
Gossamer Halves Workforce After Failed Hypertension Trial
19 Mar 2026 //
BIOSPACE
Gossamer Bio Announces Q4, Full-Year 2023 Financial Results
17 Mar 2026 //
BUSSINESSWIRE
Gossamer Bio Fails Phase 3 Pulmonary Arterial Hypertension Trial
23 Feb 2026 //
FIERCE BIOTECH
Gossamer Bio Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
08 Jan 2026 //
BUSINESSWIRE
Gossamer Bio Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
09 Dec 2025 //
BUSINESSWIRE
Gossamer Bio To Participate In Upcoming Investor Conferences
24 Nov 2025 //
BUSINESSWIRE
Gossamer Bio To Participate In Upcoming Investor Conferences
07 Nov 2025 //
BUSINESSWIRE
Gossamer Bio Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
07 Nov 2025 //
BUSINESSWIRE
Gossamer Bio Unveils Q3 2025 Financials & Business Update
05 Nov 2025 //
BUSINESSWIRE
Biotech Leader Gujrathi Holds Up A Mirror For Other Women
14 Oct 2025 //
BIOSPACE
Respira Therapeutics Enters into Agreement with Gossamer Bio
25 Sep 2025 //
PR NEWSWIRE
Gossamer Bio Announces Presentations at ERS Congress 2025
22 Sep 2025 //
BUSINESSWIRE
Gossamer Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
10 Sep 2025 //
BUSINESSWIRE
Gossamer Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
07 Aug 2025 //
BUSINESSWIRE
Gossamer Bio Reveals Q2 2025 Financial Results & Business Update
05 Aug 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Rule
06 Jun 2025 //
BUSINESSWIRE
Gossamer Bio Reports Q1 2025 Results, Updates on Prosera Study
15 May 2025 //
BUSINESSWIRE
Gossamer Bio to Announce Q1 2025 Results, Host Call on May 15
12 May 2025 //
BUSINESSWIRE
Gossamer Bio to Present Preclinical Data at ATS 2025 Conference
07 May 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Rule
07 May 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
08 Apr 2025 //
BUSINESSWIRE
Gossamer Bio Announces Q4 and Full-Year 2024 Results
13 Mar 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
07 Mar 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
07 Feb 2025 //
BUSINESSWIRE
Gossamer Bio Presents Data at Pulmonary Vascular Research Congress
03 Feb 2025 //
BUSINESSWIRE
Gossamer Bio To Present Data At Pulmonary Vascular Congress 2025
28 Jan 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
07 Jan 2025 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Rule
11 Nov 2024 //
BUSINESSWIRE
Gossamer Bio Announce Q3 2024 Financial Results & Business Update
07 Nov 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
07 Oct 2024 //
BUSINESSWIRE
Gossamer Bio To Present Data At European Respiratory Society Congress 2024
26 Aug 2024 //
BUSINESSWIRE
Gossamer Bio Announces Q2 2024 Results And Business Update
12 Aug 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Gossamer To Provide Seralutinib OLE Data At ATS 2024
14 May 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 May 2024 //
BUSINESSWIRE
Gossamer Bio Q1 2024 Results And Business Update
07 May 2024 //
BUSINESSWIRE
Gossamer Bio and Chiesi partner for pulmonary hypertension treatment
06 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Chiesi and Gossamer Bio collaborate to develop Seralutinib for PAH
06 May 2024 //
PR NEWSWIRE
Gossamer Bio and Chiesi Group collaborate on Seralutinib for pulmonary diseases.
06 May 2024 //
BUSINESSWIRE
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
06 May 2024 //
REUTERS
Gossamer: TORREY Phase 2 Data Published In Lancet Respiratory
03 May 2024 //
BUSINESSWIRE
Gossamer Bio Announces Appointment of Steven D. Nathan to its Board of Directors
12 Mar 2024 //
BUSINESSWIRE
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results
05 Mar 2024 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 Jan 2024 //
BUSINESSWIRE
Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data
13 Dec 2023 //
BUSINESSWIRE
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
05 Dec 2023 //
BUSINESSWIRE
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2023 //
BUSINESSWIRE
Gossamer Bio Announces Appointment of John Quisel to its Board of Directors
29 Nov 2023 //
BUSINESSWIRE
Gossamer Bio Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Gossamer Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
03 Oct 2023 //
BUSINESSWIRE
Gossamer Bio to Present Results of TORREY FRI Sub-Study at Congress 2023
07 Sep 2023 //
BUSINESSWIRE
Gossamer Bio Announces Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Gossamer to Hold Conference with PAH Experts to Discuss PROSERA Phase 3 Design
24 Jul 2023 //
BUSINESSWIRE
Gossamer Bio Announces $212 Million Private Placement Financing
20 Jul 2023 //
BUSINESSWIRE
